Last Updated:
10 Mar 2026, 03:30:02 PM (IST)
Morepen Laboratories Limited
NSE: MOREPENLAB BSE: MOREPENLAB
NSE
40.65
1.56 (3.99%)
Prev Close
39.09
Open Price
40
Volume
3,548,222
Today Low / High
39.54 / 40.98
52 WK Low / High
33.5 / 70.5
Range
39 - 43
BSE
40.69
1.51 (3.85%)
Prev Close
39.18
Open Price
39.55
Volume
406,250
Today Low / High
39.55 / 40.89
52 WK Low / High
33.47 / 70.4
Range
39 - 43
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 40.65 (target range: 39 - 43), reflecting a change of 1.56 (3.99079%). On the BSE, it is listed at 40.69 (target range: 39 - 43), showing a change of 1.51 (3.85401%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
Morepen Laboratories Limited Graph
Morepen Laboratories Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Morepen Laboratories Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 40.65, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 40.69 | 41.10 | 36.99 - 45.21 |
| 41.50 | 33.20 - 49.80 | ||
| 41.91 | 29.34 - 54.48 | ||
| Bearish Scenario | 40.69 | 40.28 | 36.25 - 44.31 |
| 39.88 | 31.90 - 47.85 | ||
| 39.47 | 27.63 - 51.31 |
Overview of Morepen Laboratories Limited
ISIN
INE083A01026
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
5,212,277
Market Cap
23,929,138,035
Last Dividend
0.2
Official Website
IPO Date
1996-01-01
DCF Diff
71.51
DCF
-26
Financial Ratios Every Investor Needs
Stock Dividend of MOREPENLAB
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-08-29 | August 29, 25 | 0.2 | 0.2 | 2025-08-30 | 2025-10-06 | |
| 2002-09-18 | September 18, 02 | 0.6 | 0.6 | 2002-09-23 | 2002-10-08 | 2002-07-01 |
| 2001-09-03 | September 03, 01 | 0.2 | 0.2 | 2001-09-16 | 2001-10-01 | 2001-06-16 |
| 2001-01-24 | January 24, 01 | 0.5 | 0.5 | 2001-02-09 | 2001-03-01 | 2001-01-16 |
| 2000-08-18 | August 18, 00 | 0.1 | 0.5 | 2000-09-04 | 2000-10-01 | 2000-07-18 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1,829.94 Cr | 1,199.93 Cr | 630.01 Cr | 0.3443 | 3.69 Cr | 234.18 Cr | 315.85 Cr | 118.02 Cr | 2.20 | 192.43 Cr | 0.0645 |
| 2024-03-31 | 1,701.90 Cr | 1,083.52 Cr | 618.38 Cr | 0.3633 | 5.20 Cr | 83.57 Cr | 417.38 Cr | 96.16 Cr | 1.88 | 172.60 Cr | 0.0565 |
| 2023-03-31 | 1,417.53 Cr | 955.74 Cr | 219.15 Cr | 0.1546 | 3.07 Cr | 14.16 Cr | 48.46 Cr | 38.68 Cr | 0.77 | 85.67 Cr | 0.0273 |
| 2022-03-31 | 1,541.57 Cr | 1,060.94 Cr | 480.63 Cr | 0.3118 | 3.01 Cr | 14.19 Cr | 125.54 Cr | 101.68 Cr | 2.26 | 156.77 Cr | 0.0660 |
| 2021-03-31 | 1,175.37 Cr | 786.78 Cr | 388.59 Cr | 0.3306 | 5.65 Cr | 12.17 Cr | 92.43 Cr | 97.09 Cr | 2.16 | 130.09 Cr | 0.0826 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 49.36 Cr | 1,778.10 Cr | 591.14 Cr | 1,156.2307 Cr | 105.10 Cr | 55.73 Cr | 299.97 Cr | 370.33 Cr | 0.00 Cr | 0.00 Cr | 7.17 Cr | 500.6536 Cr |
| 2024-03-31 | 16.95 Cr | 1,293.21 Cr | 445.98 Cr | 847.2262 Cr | 29.00 Cr | 12.05 Cr | 248.59 Cr | 301.30 Cr | 1.54 Cr | 0.00 Cr | 1.30 Cr | 402.0446 Cr |
| 2023-03-31 | 21.67 Cr | 1,110.50 Cr | 358.05 Cr | 752.9081 Cr | 25.16 Cr | 3.50 Cr | 228.89 Cr | 184.01 Cr | 66.37 Cr | 0.00 Cr | -33.77 Cr | 321.1631 Cr |
| 2022-03-31 | 15.80 Cr | 1,070.05 Cr | 491.95 Cr | 578.5612 Cr | 133.22 Cr | 2.77 Cr | 275.85 Cr | 160.79 Cr | 5.62 Cr | 0.00 Cr | 0.06 Cr | 456.4569 Cr |
| 2021-03-31 | 41.39 Cr | 858.15 Cr | 433.86 Cr | 424.7498 Cr | 136.70 Cr | -24.34 Cr | 175.33 Cr | 131.24 Cr | 2.86 Cr | 0.00 Cr | -26.00 Cr | 403.8000 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 32.0567 Cr | -321.5066 Cr | 299.8860 Cr | -91.9764 Cr | 10.4361 Cr | 27.3812 Cr | -124.0331 Cr | 118.0204 Cr | 76.0960 Cr | 0.0000 Cr | -51.3708 Cr |
| 2024-03-31 | 73.3746 Cr | -83.3002 Cr | 5.2049 Cr | -7.9609 Cr | -4.7207 Cr | 16.9451 Cr | -71.3808 Cr | 96.1599 Cr | 3.8351 Cr | 0.0000 Cr | -19.7079 Cr |
| 2023-03-31 | -91.1706 Cr | -46.5093 Cr | 143.5431 Cr | -137.1426 Cr | 5.8632 Cr | 21.6658 Cr | -45.9720 Cr | 55.7553 Cr | 6.5951 Cr | 0.0000 Cr | 46.9678 Cr |
| 2022-03-31 | -57.7576 Cr | -31.6785 Cr | 66.3344 Cr | -125.1256 Cr | -25.5843 Cr | 15.8026 Cr | -67.3680 Cr | 126.7026 Cr | 1.5233 Cr | 0.0000 Cr | -100.5287 Cr |
| 2021-03-31 | 50.8257 Cr | -70.3507 Cr | 47.2728 Cr | 10.4273 Cr | 27.7478 Cr | 41.3869 Cr | -40.3984 Cr | 98.5115 Cr | 3.5776 Cr | -0.4892 Cr | -36.8500 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 484.16 Cr | 297.33 Cr | 186.83 Cr | 0.3859 | 35.93 Cr | 27.51 Cr | 0.50 | 50.12 Cr | 0.0568 |
| 2025-09-30 | 411.58 Cr | 264.19 Cr | 147.38 Cr | 0.3581 | 19.41 Cr | 40.87 Cr | 0.75 | 61.16 Cr | 0.0993 |
| 2025-06-30 | 425.24 Cr | 262.36 Cr | 162.87 Cr | 0.3830 | 15.15 Cr | 10.75 Cr | 0.20 | 28.58 Cr | 0.0253 |
| 2025-03-31 | 470.46 Cr | 327.82 Cr | 142.65 Cr | 0.3032 | 73.15 Cr | 20.32 Cr | 0.35 | 37.63 Cr | 0.0432 |
| 2024-12-31 | 452.78 Cr | 290.65 Cr | 162.13 Cr | 0.3581 | 31.21 Cr | 26.69 Cr | 0.49 | 41.48 Cr | 0.0589 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 33.19 Cr | 60.10 Cr | 93.29 Cr | 274.02 Cr | 272.12 Cr | 1,036.99 Cr | 386.05 Cr | 1,736.14 Cr | 539.19 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 127.17 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -1,186.96 Cr |
| 2025-03-31 | 49.36 Cr | 77.81 Cr | 127.17 Cr | 324.76 Cr | 299.97 Cr | 1,159.37 Cr | 370.33 Cr | 1,778.10 Cr | 591.14 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 186.43 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -1,110.43 Cr |
| 2024-09-30 | 55.38 Cr | 131.04 Cr | 186.43 Cr | 300.43 Cr | 282.39 Cr | 1,092.98 Cr | 269.83 Cr | 1,562.25 Cr | 451.82 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 10.75 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 20.32 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 26.69 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 34.85 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 36.17 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2000-11-07 | November 07, 00 | 5:1 |
| 1996-09-09 | September 09, 96 | 47:40 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,812.80 | ₹4,349,514,433,616.00 | ₹3,298,187.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,372.00 | ₹1,691,565,791,760.00 | ₹298,134.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹4,427.80 | ₹1,498,568,719,232.00 | ₹373,853.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,314.60 | ₹1,094,510,791,983.00 | ₹2,328,593.00 |
| Lupin Limited | LUPIN | ₹2,337.40 | ₹1,068,292,308,200.00 | ₹1,118,737.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹923.10 | ₹928,854,596,169.00 | ₹548,985.00 |
| Mankind Pharma Limited | MANKIND | ₹2,237.70 | ₹923,733,909,614.00 | ₹1,043,890.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,285.90 | ₹746,852,807,016.00 | ₹2,197,557.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,616.50 | ₹671,536,822,500.00 | ₹127,559.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,225.80 | ₹628,122,560,672.00 | ₹1,554,299.00 |
| Laurus Labs Limited | LAURUSLABS | ₹1,038.00 | ₹560,371,132,116.00 | ₹1,367,251.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,491.20 | ₹378,323,729,882.00 | ₹56,999.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,999.90 | ₹374,794,378,438.00 | ₹123,025.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹2,117.40 | ₹339,967,004,084.00 | ₹706,890.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,567.80 | ₹297,211,828,212.00 | ₹871,597.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,815.50 | ₹220,387,500,000.00 | ₹3,477.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,327.40 | ₹215,692,105,131.00 | ₹576,727.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹1,039.20 | ₹186,130,976,904.00 | ₹2,029,982.00 |
| Eris Lifesciences Limited | ERIS | ₹1,351.10 | ₹184,042,641,430.00 | ₹100,690.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹12,597.00 | ₹161,618,111,733.00 | ₹24,766.00 |
| Granules India Limited | GRANULES | ₹581.30 | ₹141,063,489,700.00 | ₹712,670.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹712.35 | ₹140,021,741,381.00 | ₹50,451.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹812.35 | ₹128,651,664,788.00 | ₹293,109.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,684.10 | ₹128,011,297,234.00 | ₹43,345.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹940.65 | ₹115,451,618,400.00 | ₹42,515.00 |
| Cohance Lifesciences Limited | COHANCE | ₹295.60 | ₹113,086,846,584.00 | ₹907,550.00 |
| Viyash Scientific Limited | VIYASH | ₹197.45 | ₹86,151,137,188.00 | ₹1,162,070.00 |
| Procter & Gamble Health Limited | PGHL | ₹4,892.10 | ₹81,205,836,682.00 | ₹11,986.00 |
| Strides Pharma Science Limited | STAR | ₹872.90 | ₹80,457,562,051.00 | ₹160,822.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹500.60 | ₹76,642,890,235.00 | ₹265,090.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹338.65 | ₹66,233,781,988.00 | ₹758,443.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹686.70 | ₹62,254,676,925.00 | ₹118,363.00 |
| FDC Limited | FDC | ₹378.05 | ₹61,550,352,256.00 | ₹52,686.00 |
| Sequent Scientific Limited | SEQUENT | ₹202.40 | ₹50,564,340,966.00 | ₹13,647.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹124.37 | ₹40,360,749,900.00 | ₹1,617,219.00 |
| Innova Captab Limited | INNOVACAP | ₹703.35 | ₹40,249,153,812.00 | ₹21,279.00 |
| Suven Life Sciences Limited | SUVEN | ₹144.43 | ₹33,500,801,218.00 | ₹421,279.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹301.45 | ₹32,847,579,134.00 | ₹64,137.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹353.45 | ₹32,259,381,500.00 | ₹243,536.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹1,908.60 | ₹31,566,364,029.00 | ₹7,443.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹289.65 | ₹29,046,827,863.00 | ₹71,884.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹509.55 | ₹25,843,919,953.00 | ₹191,509.00 |
Key Executives
Chief Financial Officer
Ajay Kumar Sharma
Gender: male
Year Born: 1967
Head of Medipath Division
Anubhav Suri
Gender: male
Year Born: 1987
General Manager of Process Engineering & Technology Transfer
Bhola Prasad
Gender: male
Year Born:
Vice President Corporate Finance & Investor Relations
Nishant Jayesh Doshi
Gender: male
Year Born:
Whole-Time Director
Sanjay Suri
Gender: male
Year Born: 1968
Chairman & MD
Sushil Suri
Gender: male
Year Born: 1964
Functional Head of Talent Acquisition & HRBP
Vikas Sharma
Gender: male
Year Born:
Company Secretary & Compliance Officer
Vipul Kumar Srivastava
Gender: male
Year Born: 1985
Functional Head of Operations - API
Vivan Prashar
Gender: male
Year Born:
Chief Operating Officer of API
Amita Sharma
Gender: female
Year Born: 1966
Manager of Administration
Sunita Suri
Gender: female
Year Born: 1994
FAQs about Morepen Laboratories Limited
Who is the CEO of the company?
The CEO is Sushil Suri.
What is the current market price of the stock?
The current price is ₹43.67.
What is the 52-week price range?
The range is ₹33.5-70.5.
What is the market capitalization of the company?
The market capitalization is ₹2,392.91 crores.
What is the dividend yield?
The dividend yield is 0.46%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 24.16.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Morepen Laboratories Limited (ISIN: INE083A01026) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹2,392.91 crores and an average daily volume of 5,212,277 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.2.